198 related articles for article (PubMed ID: 10389656)
21. Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus.
Li Z; Sato H; Fukuda Y; Kurokawa M; Kageyama S; Kawana T; Shiraki K
Antivir Chem Chemother; 1999 Sep; 10(5):251-7. PubMed ID: 10574180
[TBL] [Abstract][Full Text] [Related]
22. Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16.
Sutton D; Boyd MR
Antimicrob Agents Chemother; 1993 Apr; 37(4):642-5. PubMed ID: 8388195
[TBL] [Abstract][Full Text] [Related]
23. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model.
Field HJ; Tewari D; Sutton D; Thackray AM
Antimicrob Agents Chemother; 1995 May; 39(5):1114-9. PubMed ID: 7625798
[TBL] [Abstract][Full Text] [Related]
24. Activity of penciclovir in antiviral assays against herpes simplex virus.
Bacon TH; Howard BA; Spender LC; Boyd MR
J Antimicrob Chemother; 1996 Feb; 37(2):303-13. PubMed ID: 8707740
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet.
Reefschläger J; Wutzler P; Thiel KD; Herrmann G
Pharm Res; 1987 Jun; 4(3):200-6. PubMed ID: 2855541
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues.
Ostrowski T; Golankiewicz B; De Clercq E; Andrei G; Snoeck R
Eur J Med Chem; 2009 Aug; 44(8):3313-7. PubMed ID: 19339082
[TBL] [Abstract][Full Text] [Related]
27. In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2.
Weinberg A; Bate BJ; Masters HB; Schneider SA; Clark JC; Wren CG; Allaman JA; Levin MJ
Antimicrob Agents Chemother; 1992 Sep; 36(9):2037-8. PubMed ID: 1329640
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the in vitro and in vivo antiherpes virus activities of the acyclic nucleosides, acyclovir (Zovirax) and 9-[(2-hydroxy-1-hydroxymethylethoxy)methyl]guanine (BWB759U).
Collins P; Oliver NM
Antiviral Res; 1985 Jun; 5(3):145-56. PubMed ID: 2992369
[TBL] [Abstract][Full Text] [Related]
29. Antiherpes effects and pharmacokinetic properties of 9-(4-hydroxybutyl) guanine and the (R) and (S) enantiomers of 9-(3,4-dihydroxybutyl)guanine.
Ericson AC; Larsson A; Aoki FY; Yisak WA; Johansson NG; Oberg B; Datema R
Antimicrob Agents Chemother; 1985 May; 27(5):753-9. PubMed ID: 2990325
[TBL] [Abstract][Full Text] [Related]
30. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
[TBL] [Abstract][Full Text] [Related]
31. Antiviral effect of chinonin against herpes simplex virus.
Jiang J; Li S; Li M; Xiang J
J Huazhong Univ Sci Technolog Med Sci; 2004; 24(5):521-4. PubMed ID: 15641710
[TBL] [Abstract][Full Text] [Related]
32. Effects of acyclovir, oxetanocin-G, and carbocyclic oxetanocin-G in combinations on the replications of herpes simplex virus type 1 and type 2 in Vero cells.
Saijo M; Suzutani T; Yoshida I
Tohoku J Exp Med; 1992 May; 167(1):57-68. PubMed ID: 1333651
[TBL] [Abstract][Full Text] [Related]
33. Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo.
Kurokawa M; Hozumi T; Tsurita M; Kadota S; Namba T; Shiraki K
J Pharmacol Exp Ther; 2001 Apr; 297(1):372-9. PubMed ID: 11259565
[TBL] [Abstract][Full Text] [Related]
34. (+-)-(1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)-cyclobutyl] guanine [(+-)-BHCG or SQ 33,054]: a potent and selective inhibitor of herpesviruses.
Field AK; Tuomari AV; McGeever-Rubin B; Terry BJ; Mazina KE; Haffey ML; Hagen ME; Clark JM; Braitman A; Slusarchyk WA
Antiviral Res; 1990 Jan; 13(1):41-52. PubMed ID: 2159261
[TBL] [Abstract][Full Text] [Related]
35. Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient.
Schnipper LE; Crumpacker CS; Marlowe SI; Kowalsky P; Hershey BJ; Levin MJ
Am J Med; 1982 Jul; 73(1A):387-92. PubMed ID: 6285729
[TBL] [Abstract][Full Text] [Related]
36. Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir.
Standring-Cox R; Bacon TH; Howard BA
J Virol Methods; 1996 Jan; 56(1):3-11. PubMed ID: 8690764
[TBL] [Abstract][Full Text] [Related]
37. The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1.
Biswas S; Jennens L; Field HJ
Antiviral Res; 2007 Jul; 75(1):30-5. PubMed ID: 17175035
[TBL] [Abstract][Full Text] [Related]
38. Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment of maintenance of latent herpes simplex virus infection in mice.
Field HJ; De Clercq E
J Gen Virol; 1981 Oct; 56(Pt 2):259-65. PubMed ID: 6273499
[TBL] [Abstract][Full Text] [Related]
39. Disease and latency characteristics of clinical herpes virus isolated after acyclovir therapy.
Sibrack CD; McLaren C; Barry DW
Am J Med; 1982 Jul; 73(1A):372-5. PubMed ID: 6285725
[TBL] [Abstract][Full Text] [Related]
40. Acyclovir treatment of cutaneous herpes in guinea pigs and herpes encephalitis in mice.
Collins P; Oliver NM
Am J Med; 1982 Jul; 73(1A):96-9. PubMed ID: 7102714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
